Benzinga | Mar 18, 2021 07:31AM EDT

Cytokinetics Highlights Recent Presentation Of Secondary Analysis From GALACTIC-HF To Be Presented In Late Breaking Clinical Trial Session At American College Of Cardiology 70th Annual Scientific Session & Expo

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction will be presented in a Late Breaking Clinical Trial session at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF.



Title 410-16 Impact Of Ejection Fraction On The Therapeutic Effect Of Omecamtiv Mecarbil In Patients With Heart Failure And Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure)

Presenter John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF

Date May 17, 2021

Session Title Late-Breaking Clinical Trials IV

Session Time 8:00 -- 9:15 AM ET

Presentation Time 9:00 -- 9:10 AM ET

About Cytokinetics